Search

Your search keyword '"Mitry E"' showing total 662 results
Start Over Author "Mitry E"
662 results on '"Mitry E"'

1. Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma

Author

Fraunhoffer, N., Hammel, P., Conroy, T., Nicolle, R., Bachet, J.-B., Harlé, A., Rebours, V., Turpin, A., Ben Abdelghani, M., Mitry, E., Biagi, J., Chanez, B., Bigonnet, M., Lopez, A., Evesque, L., Lecomte, T., Assenat, E., Bouché, O., Renouf, D.J., Lambert, A., Monard, L., Mauduit, M., Cros, J., Iovanna, J., and Dusetti, N.

Published
2024
Full Text
View/download PDF

2. Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials

Author

Adenis, A., Alessio, A., Aouakli, A., Azzedine, A., Bedjaoui, A., Bidault, A., Blanchi, A., Botton, A., Cadier-Lagnes, A., Fatisse, A., Gagnaire, A., Gilbert, A., Gueye, A., Hollebecque, A., Lemaire, A., Mahamat, A., Marre, A., Patenotte, A., Rotenberg, A., Roussel, A., Thirot-Bidault, A., Votte, A., Weber, A., Zaanan, A., Dupont-Gossart, A.C., Villing, A.L., Queuniet, A.M., Coudert, B., Denis, B., Garcia, B., Lafforgue, B., Landi, B., Leduc, B., Linot, B., Paillot, B., Rhein, B., Winkfield, B., Barberis, C., Becht, C., Belletier, C., Berger, C., Bineau, C., Borel, C., Brezault, C., Buffet, C., Cornila, C., Couffon, C., De La Fouchardière, C., Giraud, C., Lecaille, C., Lepere, C., Lobry, C., Locher, C., Lombard-Bohas, C., Paoletti, C., Platini, C., Rebischung, C., Sarda, C., Vilain, C., Briac-Levaché, C., Auby, D., Baudet-Klepping, D., Bechade, D., Besson, D., Cleau, D., Festin, D., Gargot, D., Genet, D., Goldfain, D., Luet, D., Malka, D., Peré-Vergé, D., Pillon, D., Sevin-Robiche, D., Smith, D., Soubrane, D., Tougeron, D., Zylberait, D., Carola, E., Cuillerier, E., Dorval Danquechin, E., Echinard, E., Janssen, E., Maillard, E., Mitry, E., Norguet-Monnereau, E., Suc, E., Terrebonne, E., Zrihen, E., Pariente, E.A., Almaric, F., Audemar, F., Bonnetain, F., Desseigne, F., Dewaele, F., Di Fiore, F., Ghiringhelli, F., Husseini, F., Khemissa, F., Kikolski, F., Morvan, F., Petit-Laurent, F., Riot, F., Subtil, F., Zerouala-Boussaha, F., Caroli-Bosc, F.X., Boilleau-Jolimoy, G., Bordes, G., Cavaglione, G., Coulanjon, G., Deplanque, G., Gatineau-Saillant, G., Goujon, G., Medinger, G., Roquin, G., Brixi-Benmansour, H., Castanie, H., Lacroix, H., Maechel, H., Perrier, H., Salloum, H., Senellart, H., Baumgaertner, I., Cumin, I., Graber, I., Trouilloud, I., Boutin, J., Butel, J., Charneau, J., Cretin, J., Dauba, J., Deguiral, J., Egreteau, J., Ezenfis, J., Forestier, J., Goineau, J., Lacourt, J., Lafon, J., Martin, J., Meunier, J., Moreau, J., Provencal, J., Taieb, J., Thaury, J., Tuaillon, J., Vergniol, J., Villand, J., Vincent, J., Volet, J., Bachet, J.B., Barbare, J.C., Souquet, J.C., Grangé, J.D., Dor, J.F., Paitel, J.F., Jouve, J.L., Raoul, J.L., Cheula, J.M., Gornet, J.M., Sabate, J.M., Vantelon, J.M., Vaillant, J.N., Aucouturier, J.P., Barbieux, J.P., Herr, J.P., Lafargue, J.P., Lagasse, J.P., Latrive, J.P., Plachot, J.P., Ramain, J.P., Robin, J.P., Spano, J.P., Douillard, J.Y., Beerblock, K., Bouhier-Leporrier, K., Slimane Fawzi, K., Cany, L., Chone, L., Dahan, L., Gasnault, L., Rob, L., Stefani, L., Wander, L., Baconnier, M., Ben Abdelghani, M., Benchalal, M., Blasquez, M., Carreiro, M., Charbit, M., Combe, M., Duluc, M., Fayolle, M., Gignoux, M., Giovannini, M., Glikmanas, M., Mabro, M., Mignot, M., Mornet, M., Mousseau, M., Mozer, M., Pauwels, M., Pelletier, M., Porneuf, M., Ramdani, M., Schnee, M., Tissot, M., Zawadi, M., Clavero-Fabri, M.C., Gouttebel, M.C., Kaminsky, M.C., Galais, M.P., Abdelli, N., Barrière, N., Bouaria, N., Bouarioua, N., Delas, N., Gérardin, N., Hess-Laurens, N., Stremsdoerfer, N., Berthelet, O., Boulat, O., Capitain, O., Favre, O., Amoyal, P., Bergerault, P., Burtin, P., Cassan, P., Chatrenet, P., Chiappa, P., Claudé, P., Couzigou, P., Feydy, P., Follana, P., Geoffroy, P., Godeau, P., Hammel, P., Laplaige, P., Lehair, P., Martin, P., Novello, P., Pantioni, P., Pienkowski, P., Pouderoux, P., Prost, P., Ruszniewski, P., Souillac, P., Texereau, P., Thévenet, P., Haineaux, P.A., Benoit, R., Coriat, R., Lamy, R., Mackiewicz, R., Beorchia, S., Chaussade, S., Hiret, S., Jacquot, S., Lavau Denes, S., Montembault, S., Nahon, S., Nasca, S., Nguyen, S., Oddou-Lagraniere, S., Pesque-Penaud, S., Fratte, S.P., Chatellier, T., Mansourbakht, T., Morin, T., Walter, T., Boige, V., Bourgeois, V., Derias, V., Guérin-Meyer, V., Hautefeuille, V., Jestin Le Tallec, V., Lorgis, V., Quentin, V., Sebbagh, V., Veuillez, V., Adhoute, X., Coulaud, X., Becouarn, Y., Coscas, Y., Courouble, Y., Le Bricquir, Y., Molin, Y., Rinaldi, Y., Lam, Y.H., Ladhib, Z., Aparicio, Thomas, Ducreux, Michel, Faroux, Roger, Barbier, Emilie, Manfredi, Sylvain, Lecomte, Thierry, Etienne, Pierre-Luc, Bedenne, Laurent, Bennouna, Jaafar, Phelip, Jean-Marc, François, Eric, Michel, Pierre, Legoux, Jean-Louis, Gasmi, Mohamed, Breysacher, Gilles, Rougier, Philippe, De Gramont, Aimery, Lepage, Come, Bouché, Olivier, and Seitz, Jean-François

Published
2018
Full Text
View/download PDF

3. Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001–02)

Author

Aparicio, T., Lavau-Denes, S., Phelip, J.M., Maillard, E., Jouve, J.L., Gargot, D., Gasmi, M., Locher, C., Adhoute, X., Michel, P., Khemissa, F., Lecomte, T., Provençal, J., Breysacher, G., Legoux, J.L., Lepère, C., Charneau, J., Cretin, J., Chone, L., Azzedine, A., Bouché, O., Sobhani, I., Bedenne, L., Mitry, E., Amoyal, P., Auby, D., Bachet, J.B., Baconnier, M., Benoit, R., Berthelet, O., Bidault, A., Bineau, C., Bordes, G., Bouarioua, N., Boucher, E., Boulat, O., Cleau, D., Couzigou, P., Cuillerier, E., Cumin, I., Denis, B., Di Fiore, F., Derias, V., Ezenfis, J., Faroux, R., Gagnaire, A., Gatineau-Sailliant, G., Garcia, B., Genet, D., Gueye, A., Hammel, P., Lagasse, J.P., Landi, B., Lepage, C., Lobry, C., Lombard-Bohas, C., Mabro, M., Mackiewicz, R., Martin, J., Moncoucy, X., Morvan, F., Mozer, M., Pauwels, M., Petit-Laurent, F., Pouderoux, P., Prost, P., Queuniet, A.M., Ramdani, M., Rebischung, C., Rougier, P., Schnee, M., Seitz, J.F., Stefani, L., Taïeb, J., Terrebonne, E., Texereau, P., Thaury, J., Tougeron, D., Weber, A., Ricard, F., Bonnetain, F., Masskouri, F., Choine, C., Guiliani, F., Le Pessec, G., Fattouh, H., Le Provost, N., Girault, C., and Schneider, M.

Published
2016
Full Text
View/download PDF

5. 562P Acquired genomic alterations on first-line chemotherapy (CT) + cetuximab in advanced colorectal cancer (mCRC): Circulating tumor (ct)DNA analysis of the randomized phase II trial TIME-PRODIGE-28

Author

Boige, V., Bouche, O., Mulot, C., Evesque, L., Ben Abdelghani, M., Phelip, J.M., Mineur, L., Galais, M.P., Villing, A-L., Hautefeuille, V., Fouchardiere, C. de la, Genet, D., Lassoued, S., Carnot, A., Mitry, E., Jacquot, S., Serazin, D., Brument, E., Winter, A., and Blons, H.

Published
2024
Full Text
View/download PDF

6. Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict adjuvant chemosensitivity in pancreatic cancer

Author

Nicolle, R., primary, Gayet, O., additional, Bigonnet, M., additional, Roques, J., additional, Chanez, B., additional, Puleo, F., additional, Augustin, J., additional, Emile, J.F., additional, Svrcek, M., additional, Arsenijevic, T., additional, Hammel, P., additional, Rebours, V., additional, Giovannini, M., additional, Grandval, P., additional, Dahan, L., additional, Moutardier, V., additional, Mitry, E., additional, Van Laethem, J.L., additional, Bachet, J.B., additional, Cros, J., additional, Iovanna, J., additional, and Dusetti, N.J., additional

Published
2022
Full Text
View/download PDF

11. LBA57 Unicancer PRODIGE 24/CCTG PA6 trial: Updated results of a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas (PDAC)

Author

Conroy, T., primary, Hammel, P., additional, Turpin, A., additional, Belletier, C., additional, Wei, A., additional, Mitry, E., additional, Lopez, A., additional, Francois, E., additional, Artru, P., additional, Biagi, J., additional, Lecomte, T., additional, Assenat, E., additional, Faroux, R., additional, Ychou, M., additional, Bouche, O., additional, Lambert, A., additional, Monard, L., additional, Rat, P., additional, Castan, F., additional, and Bachet, J-B., additional

Published
2021
Full Text
View/download PDF

16. 138P Precision medicine phase II study evaluating the efficacy of olaparib in patients with progressive solid cancers and carriers of homologous recombination repair genes alterations

Author

Polito, M., Le Tourneau, C., DeMontfort, A., Cousin, S., Toulmonde, M., Gomez-Roca, C.A., Bourcier, K., Korakis, I., Bertucci, F., Mitry, E., Mazza, C., Cassier, P., Coutzac, C., Italiano, A., Attignon, V.K., Mayet, R., Perol, D., Sablin, M.P., Blay, J-Y., and Tredan, O.

Published
2023
Full Text
View/download PDF

26. Revue De Presse

Author

Bulois, P., Mitry, E., Bigard, M. -A., Senéjoux, A., Siproudhis, L., Panis, Y., and Alves, A.

Published
2007
Full Text
View/download PDF

37. New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel†

Author

Van Laethem, J.-L., Verslype, C., Iovanna, J. L., Michl, P., Conroy, T., Louvet, C., Hammel, P., Mitry, E., Ducreux, M., Maraculla, T., Uhl, W., Van Tienhoven, G., Bachet, J. B., Maréchal, R., Hendlisz, A., Bali, M., Demetter, P., Ulrich, F., Aust, D., Luttges, J., Peeters, M., Mauer, M., Roth, A., Neoptolemos, J. P., and Lutz, M.

Published
2012
Full Text
View/download PDF

45. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers

Author

O'Toole, D., Grossman, A., Gross, D., Fave, G. D., Barkmanova, J., O'Connor, J., Pape, U. F., Plöckinger, U., Åkerström, G., Annibale, B., Arnold, R., Bajetta, E., Chen, Y. J., Costa, F., Couvelard, A., Davar, J., Herder, W. D., Eriksson, B., Falconi, M., Ferone, D., Gustafsson, B., Hyrdel, R., Ivan, D., Kaltsas, G., Kianmanesh, R., Klöppel, G., Knigge, U. P., Komminoth, P., Kos Kudla, B., Kwekkeboom, D., Lebtahi, R., Lewington, V., Mcnicol, A. M., Mitry, E., Nilsson, O., Öberg, K., Papotti, M., Pavel, M., Perren, A., Platania, M., Rindi, G., Ruszniewski, P., Salazar, R., Scarpa, Aldo, Scheidhauer, K., Scoazec, J. Y., Sundin, A., Szpak, W., Taal, B., Vitek, P., Vullierme, M. P., and Wiedenmann, B.

Subjects
Endocrinology, Diabetes and Metabolism, Diagnostic accuracy, insulinoma, Neuroendocrine tumors, Bioinformatics, secretin, 0302 clinical medicine, Endocrinology, immune system diseases, cancer diagnosis, conference paper, Biochemical markers, biology, Urinary 5-hydroxyindoleacetic acid, Chromogranin A, Fasting, Hydroxyindoleacetic Acid, Diabetes and Metabolism, Neuroendocrine Tumors, priority journal, 030220 oncology & carcinogenesis, diagnostic accuracy, 5 hydroxyindoleacetic acid, neuroendocrine tumor, hormones, hormone substitutes, and hormone antagonists, Neuroendocrine tumor test, musculoskeletal diseases, medicine.medical_specialty, Standard of care, MEDLINE, 610 Medicine & health, 030209 endocrinology & metabolism, 03 medical and health sciences, Cellular and Molecular Neuroscience, Patient information, Internal medicine, gastrin, medicine, Humans, biochemistry, human, Insulinoma, Gastrinoma, gastrinoma, Endocrine and Autonomic Systems, business.industry, practice guideline, biochemical marker, chromogranin A, hypoglycemia, patient information, medicine.disease, body regions, biology.protein, 570 Life sciences, Biomarkers, business
Abstract

Biomarkers have been the mainstay in the diagnosis and follow-up of patients with neuroendocrine tumors (NETs) over the last few decades. In the beginning, secretory products from a variety of subtypes of NETs were regarded as biomarkers to follow during diagnosis and treatment: serotonin for small intestinal (SI) NETs, and gastrin and insulin for pancreatic NETs. However, it became evident that a large number of NETs were so-called nonfunctioning tumors without secreting substances that caused hormone-related symptoms. Therefore, it was necessary to develop so-called “general tumor markers.” The most important ones so far have been chromogranin A and neuron-specific enolase (NSE). Chromogranin A is the most important general biomarker for most NETs with a sensitivity and specificity somewhere between 60 and 90%. NSE has been a relevant biomarker for patients with high-grade tumors, particularly lung and gastrointestinal tract tumors. Serotonin and the breakdown product urinary 5-hydroxyindoleacetic acid (U-5-HIAA) is still an important marker for diagnosing and follow-up of SI NETs. Recently, 5-HIAA in plasma has been analyzed by high-performance liquid chromatography and fluorometric detection and has shown good agreement with U-5-HIAA analysis. In the future, we will see new tests including circulating tumor cells, circulating DNA and mRNA. Recently, a NET test has been developed analyzing gene transcripts in circulating blood. Preliminary data indicate high sensitivity and specificity for NETs. However, its precise role has to be validated in prospective randomized controlled trials which are ongoing right now.

Published
2017
Full Text
View/download PDF

49. Chemoembolization of Neuroendocrine Liver Metastases Using Streptozocin and Tris-acryl Microspheres: Embozar (EMBOsphere + ZAnosaR) Study

Author

Pelage, J-P, Fohlen, A, Mitry, E, Lagrange, C, Beauchet, A, Rougier, P, Service d'Imagerie Diagnostique et de Radiologie Thérapeutique [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Hypoxie, physiopathologies cérébrovasculaire et tumorale (CERVOxy), Imagerie et Stratégies Thérapeutiques des pathologies Cérébrales et Tumorales (ISTCT), Normandie Université (NU)-Normandie Université (NU)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS)-Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Department of Hepatogastroenterology and Oncology, Hopital Ambroise Pare, 9, Avenue Charles de Gaulle, 92104, Boulogne Cedex, France., Hôpital Ambroise Paré [AP-HP], Department of Radiology, Hopital Ambroise Pare, 9, Avenue Charles de Gaulle, 92104, Boulogne Cedex, France., Department of Biostatistics and Public Health, Hopital Ambroise Pare, 9, Avenue Charles de Gaulle, 92104, Boulogne Cedex, France., Centre National de la Recherche Scientifique (CNRS)-Université de Caen Normandie (UNICAEN), and Normandie Université (NU)-Normandie Université (NU)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)

Subjects
Adult, Male, [SDV]Life Sciences [q-bio], Acrylic Resins, Streptozocin, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, Ethiodized Oil, 0302 clinical medicine, Endocrine Gland Neoplasms, Humans, Radiology, Nuclear Medicine and imaging, Prospective Studies, Chemoembolization, Therapeutic, Aged, Antibiotics, Antineoplastic, Liver Neoplasms, Middle Aged, Magnetic Resonance Imaging, 3. Good health, Treatment Outcome, Liver, Arterial, Gelatin, Female, Chemoembolization, Neuroendocrine tumors, Tomography, X-Ray Computed, Cardiology and Cardiovascular Medicine
Abstract

The purpose of this prospective observational study was to evaluate the efficacy and tolerability of transarterial chemoembolization (TACE) for neuroendocrine liver metastases using a combination of streptozocin, Lipiodol, and tris-acryl microspheres.A total of 16 men and 9 women aged 59.6 ± 11.3 years, all with predominant liver disease, underwent 54 courses of TACE using an emulsion of 1.5 g of streptozocin and 10 ml of Lipiodol. Additional embolization was performed using 300-500 µm tris-acryl microspheres. Morphological response was evaluated using the RECIST criteria on multi-detector computed tomography or MRI. Clinical efficacy was evaluated particularly in patients with carcinoid syndrome.The primary tumor was located in the small bowel or pancreas in 21 (84%) patients. Eleven (44%) patients presented with a carcinoid syndrome. Nineteen (76%) patients presented with more than 10 liver nodules. One delayed case of ischemic cholecystitis was treated conservatively. After a median follow-up of 36.1 months, 1 (4%) patient had a complete response, 12 (48%) patients had a partial response, and 7 (28%) patients had a stable disease corresponding to a disease control rate of 80%. All patients with carcinoid syndrome had significant improvement. Median time to progression was 18.8 months and overall survival was 100, 100, and 92% at 1, 2, and 3 years, respectively. Seven patients presented with extrahepatic progression with abdominal lymphadenopathies or metastases to the brain, ovary, adrenal gland, or lung.Optimized TACE using a combination of streptozocin, Lipiodol, and tris-acryl microspheres is effective and well tolerated.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results